Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
Blood Advances|July 17, 2026
Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemiaXiancheng Wu, Mazyar Shadman, Jenna M Voutsinas, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Frontiers in Immunology|August 1, 2022
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced MalignanciesHao Huang, Ling Peng, Bicheng Zhang, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
Blood|February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBrian G Till, Michael C Jensen, Jinjuan Wang, et al.
JCO Clinical Cancer Informatics|January 14, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based ModelsEmily C Liang, Yein Jeon, Yang Qiao, et al.
Blood Advances|September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.
Pageof 8